Improved virus purification processes for vaccines and gene therapy

Biotechnology and Bioengineering

Volumn 112, Issue 5, 2015, Pages 843-857

  Nestola, Piergiuseppe ^a,b   Peixoto, Cristina ^a,b   Silva, Ricardo R J S ^a   Alves, Paula M ^a,b   Mota, José P B ^a,c   Carrondo, Manuel J T ^a,c  

^a INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Continuous purification; Downstream bioprocessing; Gene therapy; Process intensification; Vaccines

Indexed keywords

GENES; PURIFICATION; VACCINES; VIRUSES;

BIOPROCESSING; BREAKTHROUGH TECHNOLOGY; DOWNSTREAM PURIFICATIONS; DOWNSTREAM-PROCESSING; PHARMACEUTICAL QUALITY; PROCESS INTENSIFICATION; PROCESS UNDERSTANDING; VIRUS PURIFICATION;

GENE THERAPY;

VIRUS VACCINE; VACCINE;

CELL DENSITY; CHROMATOGRAPHY; CYTOLYSIS; DENSITY GRADIENT CENTRIFUGATION; DOWNSTREAM PROCESSING; EXPANDED BED CHROMATOGRAPHY; GEL PERMEATION CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; NONHUMAN; PROCESS DEVELOPMENT; REVIEW; ULTRAFILTRATION; VACCINATION; VIRAL GENE THERAPY; VIRUS PARTICLE; VIRUS PURIFICATION; ANIMAL; BIOTECHNOLOGY; GENE THERAPY; HUMAN; ISOLATION AND PURIFICATION; PHARMACEUTICS; PROCEDURES; VIRION; VIRUS;

ANIMALS; BIOTECHNOLOGY; CENTRIFUGATION, DENSITY GRADIENT; CHROMATOGRAPHY; GENETIC THERAPY; HUMANS; TECHNOLOGY, PHARMACEUTICAL; ULTRAFILTRATION; VACCINES; VIRION; VIRUSES;

EID: 84925689348     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25545     Document Type: Review

References (159)

1. Altaras NE, Aunins JG, Evans RK, Kamen A, Konz JO, Wolf J. 2005. Production and formulation of adenovirus vectors. Adv Biochem Eng Biotechnol 99:193-260.
2. Antony A, Blackbeard J, Angles M, Leslie G. 2014. Non-microbial indicators for monitoring virus removal by ultrafiltration membranes. J Membr Sci 454:193-199.
3. Aumann L, Morbidelli M. 2007. A continuous multicolumn countercurrent solvent gradient purification (MCSGP) process. Biotechnol Bioeng 98:1043-1055.
4. Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick K, Perry J, Zablowsky E, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH. 2013. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207: 240-247.
5. Bajpai A, Bajpai J, Saini R, Gupta R. 2011. Responsive polymers in biology and technology. Polymer Rev 51:53-97.
6. Bandeira VS, Peixoto C, Rodrigues AF, Cruz P, Alves P, Coroadinha AS, Carrondo M. 2012. Downstream Processing of Lentiviral Vectors: Releasing bottlenecks. Hum Gene Ther Methods 23:255-263.
7. Banjac M, Roethl E, Gelhart F, Kramberger P, Jarc BL, Jarc M, Strancar A, Muster T, Peterka . 2014. Purification of Vero cell derived live replication deficient in influenza A and B virus by ion exchange monolith chromatography. Vaccine 32:2487-2492.
8. Barut M, Podgornik A, Brne P, Strancar A. 2005. Convective interaction media short monolithic columns: Enabling chromatographic supports for the separation and purification of large biomolecules. J Sep Sci 28:1876-1892.
9. Benavides J, Mena JA, Cisneros-Ruiz M, Ramirez OT, Palomares L, Rito-Palomares M. 2006. Rotavirus-like particles primary recovery from insect cells in aqueous two-phase systems. J Chromatogr B 842:48-57.
10. Bencina K, Bencina M, Podgornik A, Strancar A. 2007. In uence of the methacrylate monolith structure on genomic DNA mechanical degradation, enzymes activity and clogging. J Chromatogr A 1160:176-183.
11. Blom H, Akerblom A, Kon T, Shaker S, van der Pol L, Lundgren M. 2014. Efficient chromatographic reduction of ovalbumin for egg-based influenza virus purification. Vaccine 32:3721-3724.
12. Bochenek R, Marek W, Piatkowski W, Antos D. 2013. Evaluating the performance of different multicolumn setups for chromatographic separation of proteins on hydrophobic interaction chromatography media by a numerical study. J Chromatogr A 1301:60-72.
13. Boychyn M, Yim S, Ayazi Shamlou P, Bulmer M, More J, Hoare M. 2001. Characterization of flow intensity in continuous centrifuges for the development of laboratory mimics. Chem Eng Sci 56:4759-4770.
14. Brooks CA, Cramer SM. 1992. Steric mass action ion exchange: Displacement profiles and induced salt gradients. AIChE J. 38: 1969-1978.
15. Cameron-Smith R, Harbour C. 2001. Removal of poliovirus type 1 from a protein mixture using an immunoaffinity chromatography column. Biomed Chromatogr 15:471-483.
16. Castino F, Wickramasinghe S. 1996. Washing frozen red blood cell concentrates using hollow fibers. J Membr Sci 110:169-180.
17. Chackerian B. 2007. Virus-like particles: Flexible platforms for vaccine development. Expert Rev Vaccines 6:381-390.
18. Chahal PS, Aucoin MG, Kamen A. 2007. Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. J Virol Methods 139:61-70.
19. Chatel A, Kumpalume P, Hoare M. 2014. Ultra scale-down characterization of the impact of conditioning methods for harvested cell broths on clarification by continuous centrifugation recovery of domain antibodies from rec E. coli. Biotechnol Bioeng 111:913-924.
20. Chuan YP, Wibowo N, Lua LH, Middelberg AP. 2014. The economics of virus-like particle and capsomere vaccines. Biochem Eng J 90:255-263.
21. Cramer SM, Holstein MA. 2011. Downstream bioprocessing: Recent advances and future promise. Curr Opin Chem Eng 1:27-37.
22. Diederich P, Amrhein S, Hämmerling F, Hubbuch J. 2013. Evaluation of PEG/phosphate aqueous two-phase systems for the purification of the chicken egg white protein avidin by using high-throughput techniques. Chem Eng Sci 104:945-956.
23. D'Souza RN, Azevedo AM, Aires-Barros MR, Krajnc NL, Kramberger P, Carbajal ML, Grasselli M, Meyer R, Fernández-Lahore M. 2013. Emerging technologies for the integration and intensification of downstream bioprocesses. Pharm Bioprocess 1:423-440.
24. Eglon MN, Duffy AM, O'Brien T, Strappe PM. 2009. Purification of adenoviral vectors by combined anion exchange and gel filtration chromatography. J Gene Med 11:978-989.
25. EMEA, 1999. Specifications: Test procedures and acceptance criteria for biotechnological/ biological products. ICH Q6B.
26. Ewer K, OHara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV. 2013. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4:2836.
27. Farid SS. 2007. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B 848:8-18.
28. FDA Briefing Document. 2012. Vaccines and Related Biological Products Advisory Committee Meeting. Cell Lines Derived from Human Tumors for Vaccine Manufacture. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM319573.pdf .
29. Fee C, Nawada S, Dimartino S. 2014. 3D printed porous media columns with fine control of column packing morphology. J Chromatogr A 1333:18-24.
30. Fernandes P, Peixoto C, Santiago VM, Kremer EJ, Coroadinha AS, Alves PM. 2012. Bioprocess development for canine adenovirus type 2 vectors. Gene Ther 20:353-360.
31. Fischer R, Stoger E, Schillberg S, Christou P, Twyman RM. 2004. Plant-based production of biopharmaceuticals. Curr Opin Plant Biol 7:152-158.
32. Forcic D, Brgles M, Ivancic-Jelecki J, Šantak M, Halassy B, Barut M, Jug R, Markuši M, Štrancar A. 2011. Concentration and purification of rubella virus using monolithic chromatographic support. J Chromatogr B 879:981-986.
33. Francotte ER, Richert P. 1997. Applications of simulated moving-bed chromatography to the separation of the enantiomers of chiral drugs. J Chromatogr A 769:101-107.
34. Freeman GJ, McKechnie MT. 2003. Filtration and Stabilization of Beers (pp. 365-392). Springer.
35. Gadam SD, Jayaraman G, Cramer SM. 1993. Characterization of non-linear adsorption properties of dextran-based polyelectrolyte displacers in ion-exchange systems. J Chromatogr A 630:37-52.
36. Geels M, Ye K. 2010. Developments in high-yield system expressed vaccines and immunotherapy. Recent Pat Biotechnol 4:189.
37. Genzel Y, Vogel T, Buck J, Behrendt I, Ramirez DV, Schiedner G, Jordan I, Reichl U. 2014. High cell density cultivations by alternating tangential ow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 32:2770-2781.
38. Gerster P, Kopecky E-M, Hammerschmidt N, Klausberger M, Krammer F, Grabherr R, Mersich C, Urbas L, Kramberger P, Paril T, Schreiner M, Nöbauer K, Razzazi-Fazeli E, Jungbauer A. 2013. Purification of infective baculoviruses by monoliths. J Chromatogr A 1290:36-45.
39. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. 2013. Gene therapy clinical trials worldwide to 2012 an update. J Gene Med 15:65-77.
40. Godawat R, Brower K, Jain S, Konstantinov K, Riske F, Warikoo V. 2012. Periodic countercurrent chromatography-design and operational considerations for integrated and continuous puri cation of proteins. Biotechnol J 7:1496-1508.
41. Goerke AR, To BCS, Lee AL, Sagar SL, Konz JO. 2005. Development of a novel adenovirus purification process utilizing selective precipitation of cellular DNA. Biotechnol Bioeng 91:12-21.
42. González-González M, Rito-Palomares M. 2013. Aqueous two-phase systems strategies to establish novel bioprocesses for stem cells recovery. Crit Rev Biotech 0738-8551:1-10.
43. Gottschalk U. 2010. Disposables in downstream processing. Adv Biochem Eng Biotechnol 115:171-183.
44. Gottschalk U, Brorson K, Shukla AA. 2013. Innovation in biomanufacturing: The only way forward. Pharm Bioproces 1:141-157.
45. Grzenia DL, Carlson JO, Wickramasinghe SR. 2008. Tangential flow filtration for virus purification. J Membr Sci 321:373-380.
46. Guo P, El-Gohary Y, Prasadan K, Shiota C, Xiao X, Wiersch J, Paredes J, Tulachan S, Gittes GK. 2012. Rapid and simplified purification of recombinant adeno-associated virus. J Virol Methods 183:139-146.
47. Hardick O, Dods S, Stevens B, Bracewell DG. 2012. Nano fiber adsorbents for high productivity downstream processing. Biotechnol Bioeng 110:1119-1128.
48. Hibbert DB. 2012. Experimental design in chromatography: A tutorial review. J Chromatogr B 910:2-13.
49. ICH, 1999. Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Q5A(R1).
50. ICH, 2007. Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions. ICH Q4B.
51. Iyer G, Ramaswamy S, Asher D, Mehta U, Leahy A, Chung F, Cheng K-S. 2011. Reduced surface area chromatography for flow-through purification of viruses and virus like particles. J Chromatogr A 1218:3973-3981.
52. Jarvis DL. 2009. Baculovirus-Insect Cell Expression Systems. Methods Enzymol 463:191-222.
53. Josefsberg JO, Buckland B. 2012. Vaccine process technology. Biotechnol Bioeng 109:1443-1460.
54. Jungbauer A. 2013. Continuous downstream processing of biopharmaceuticals. Trends Biotechnol 31:479-492.
55. Kalbfuss B, Genzel Y, Wolff M, Zimmermann A, Morenweiser R, Reichl U. 2007. Harvesting and concentration of human in influenza A virus produced in serum-free mammalian cell culture for the production of vaccines. Biotechnol Bioeng 97:73-85.
56. Kamen A, Henry O. 2004. Development and optimization of an adenovirus production process. J Gene Med 6:S184-S192.
57. Kanani DM, Ghosh R. 2007. A constant flux based mathematical model for predicting permeate flux decline in constant pressure protein ultrafiltration. J Membr Sci 290:207-215.
58. Kang SM, Kim MC, Compans RW. 2012a. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 11:995-1007.
59. Kang YK, Ng S, Lee J, Adaelu J, Qi B, Persaud K, Ludwig D, Balderes P. 2012b. Development of an alternative monoclonal antibody polishing step. BioPharm International 25:34-46.
60. Kashiwagi S, Yuan J, Forbes B, Hibert ML, Lee EL, Whicher L, Goudie C, Yang Y, Chen T, Edelblute B, Collette B, Edington L, Trussler J, Nezivar J, Leblanc P, Brauns T, Gelfand J, Poznansky MC. 2013. Near-Infrared laser adjuvant for in influenza vaccine. PloS one 8:e82899.
61. Konz JO, Lee AL, Lewis JA, Sagar SL. 2005. Development of a purification process for adenovirus: Controlling virus aggregation to improve the clearance of host cell DNA. Biotechnol Prog 21:466-472.
62. Koutsonanos DG, del Pilar M, Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, Skountzou I. 2009. Transdermal influenza immunization with vaccine coated microneedle arrays. PloS one 4:e4773.
63. Kröber T, Knöchlein A, Eisold K, Kalbfuss-Zimmermann B, Reichl U. 2010. DNA Depletion by precipitation in the purification of cell culture-derived influenza vaccines. Chem Eng Technol 33:941-959.
64. Kröber T, Wolff M, Hundt B, Seidel-Morgenstern A, Reichl U. 2013. Continuous purification of influenza virus using simulated moving bed chromatography. J Chromatogr A 1307:99-110.
65. Ladiwala A, Rege K, Breneman CM, Cramer SM. 2005. A priori prediction of adsorption isotherm parameters and chromatographic behavior in ion-exchange systems. Proc Natl Acad Sci U.S.A. 102:11710-11715.
66. Lee D-S, Kim B-M, Seol D-W. 2009. Improved purification of recombinant adenoviral vector by metal affinity membrane chromatography. Biochem Biophys Res Commun 378:640-644.
67. Lee J, Gan HT, Latiff SMA, Chuah C, Lee WY, Yang YS, Loo B, Ng SK, Gagnon P. 2012. Principles and applications of steric exclusion chromatography. J Chromatogr A 1270:162-170.
68. Lee MFX, Chan ES, Tey BT. 2014. Negative chromatography: Progress, applications and future perspectives. Process Biochem 49:1005-1011.
69. Li Y, Liu X, Dong X, Zhang L, Sun Y. 2014. Biomimetic design of affinity peptide ligand for capsomere of virus-like particle. Langmuir 30:8500-8508.
70. Liniger M, Zuniga A, Naim HY. 2007. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6:255-266.
71. Liu HF, Ma J, Winter C, Bayer R. 2010. Recovery and purification process development for monoclonal antibody production. MAbs 2:480-499.
72. Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg A. 2013. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 111:425-440.
73. Luechau F, Ling TC, Lyddiatt A. 2011. Recovery of B19 virus-like particles by aqueous two-phase systems. Food Bioprod Process 89:322-327.
74. Lusky M. 2005. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther 16:281-291.
75. Mahajan E, George A, Wolk B. 2012. Improving affinity chromatography resin efficiency using semi-continuous chromatography. J Chromatogr A 1227:154-162.
76. Majhen D, Calderon H, Chandra N, Fajardo C, Rajan A, Alemany R, Custers J. 2014. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther 25:301-317.
77. Makinen M, Kaddar M, Molldrem V, Wilson L. 2012. New vaccine adoption in lower-middleincome countries. Health Policy Plan. 27:39-49.
78. Margine I, Martinez-Gil L, Chou YY, Krammer F. 2012. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PloS one 7:e51559.
79. McConnell MJ. 2009. Adenovirus as a Vaccine Platform. ProQuest.
80. McCurdy V, Migliaccio G, Nosal R, Spavins J. 2011. A Pharma Manufacturer's View of Quality by Design. Pharm Technol 35:S34-S39.
81. McNally D, Darling D, Farzaneh F, Levison P, Slater N. 2014. Optimised concentration and purification of retroviruses using membrane chromatography. J Chromatogr A 1340:24-32.
82. Mehta A, Zydney AL. 2005. Permeability and selectivity analysis for ultrafiltration membranes. J Memb Sci 249:245-249.
83. de las Mercedes Segura M, Kamen A, Lavoie M-C, Garnier A. 2007. Exploiting heparin-binding properties of MoMLV-based retroviral vectors for affinity chromatography. J Chromatogr B 846:124-131.
84. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. 2011. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29:9127-9131.
85. Morenweiser R. 2005. Downstream processing of viral vectors and vaccines. Gene Ther 12:103-110.
86. Nardin E. 2010. The past decade in malaria synthetic peptide vaccine clinical trials. Hum Vaccin 6:27-38.
87. Nébié I, Edwards NJ, Tiono AB, Ewer KJ, Sanou GS, Soulama I, Sanon S, Diarra A, Yaro JB, Kangoye D, Imoukhuede EB, Hill AV, Sirima SB. 2014. Assessing chimpanzee adenovirus serotype 63 (ChAd63) neutralizing antibodies prior to the evaluation of a candidate malaria vaccine regimen based on viral vectors. Clin Vaccine Immunol 21:901-903.
88. Negrete A, Ling TC, Lyddiatt A. 2007. Production of adenoviral vectors and its recovery. Process Biochem 42:1107-1113.
89. Negrete A, Pai A, Shiloach J. 2014. Use of hollow fiber tangential flow filtration for the recovery and concentration of HIV virus-like particles produced in insect cells. J Virol Methods 195:240-246.
90. Nestola P, Silva RJ, Peixoto C, Alves PM, Carrondo MJ, Mota JP. 2014a. Adenovirus purification by two-column, size-exclusion, simulated countercurrent chromatography. J Chromatogr A 1347:111-121.
91. Nestola P, Villain L, Peixoto C, Martins DL, Alves PM, Carrondo MJ, Mota JP. 2014b. Impact of grafting on the design of new membrane adsorbers for adenovirus purification. J Biotechnol 181:1-11.
92. Nfor BK, Ahamed T, Pinkse MW, van der Wielen L, Verhaert PD, van Dedem GM, Eppink MH, van de Sandt EJ, Ottens M. 2012a. Multi-dimensional fractionation and characterization of crude protein mixtures: Toward establishment of a database of protein purification process development parameters. Biotechnol Bioeng 109:3070-3083.
93. Nfor BK, Ripić J, van der Padt A, Jacobs M, Ottens M. 2012b. Model-based highthroughput process development for chromatographic whey proteins separation. Biotechnol J 7:1221-1232.
94. Nfor BK, Verhaert PD, van der Wielen LA, Hubbuch J, Ottens M. 2009. Rational and systematic protein purification process development: The next generation. Trends Biotechnol 27:673-679.
95. Nicoud R-M. 2014. The amazing ability of continuous chromatography to adapt to a moving environment. Ind Eng Chem Res 53:3755-3765.
96. Oelmeier SA, Dismer F, Hubbuch J. 2010. Application of an aqueous two-phase systems high-throughput screening method to evaluate mAb HCP separation. Biotechnol Bioeng 108:69-81.
97. Oelmeier SA, Ladd Effio C, Hubbuch J. 2012. High throughput screening based selection of phases for aqueous two-phase system-centrifugal partitioning chromatography of monoclonal antibodies. J Chromatogr A 1252:104-114.
98. Opitz L, Hohlweg J, Reichl U, Wolff MW. 2009. Purification of cell culture-derived influenza virus A/Puerto Rico/8/34 by membrane-based immobilized metal affinity chromatography. J Virol Methods 161:312-316.
99. Osberghaus A, Drechsel K, Hansen S, Hepbildikler S, Nath S, Haindl M, Von Lieres E, Hubbuch J. 2012a. Model-integrated process development demonstrated on the optimization of a robotic cation exchange step. Chem Eng Sci 76:129-139.
100. Osberghaus A, Hepbildikler S, Nath S, Haindl M, von Lieres E, Hubbuch J. 2012b. Determination of parameters for the steric mass action model. A comparison between two approaches. J Chromatogr A 1233:54-65.
101. Ostreicher EA, Arnold TE, Conway RS. 2008. Charge Modified Filter Media (pp. 23-46). Informa Healthcare.
102. Ouédraogo A, Tiono AB, Kargougou D, Yaro JB, Ouédraogo E, Kaboré Y, Kangoye D, Bougouma EC, Gansane A, Henri N, Diarra A, Sanon S, Soulama I, Konate AT, Watson NL, Brown V, Hendriks J, Pau MG, Versteege I, Wiesken E, Sadoff J, Nebie I, Sirima SB. 2013. A phase 1b randomized, Controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in burkinabe healthy adults 18 to 45 years of age. PloS one 8:e78679.
103. Oyston P, Robinson K. 2012. The current challenges for vaccine development. J Med Microbiol 61:889-894.
104. Paulen R, Fikar M, Foley G, Kovács Z, Czermak P. 2012. Optimal feeding strategy of diafiltration buffer in batch membrane processes. J Membr Sci 411:160-172.
105. Peinador R, Calvo JI, ToVinh K, Thom V, Prádanos P, Hernández A. 2011. Liquid-liquid displacement porosimetry for the characterization of virus retentive membranes. J Membr Sci 372:366-372.
106. Peixoto C, Ferreira T, Carrondo M, Cruz P, Alves P. 2006. Purification of adenoviral vectors using expanded bed chromatography. J Virol Methods 132:121-126.
107. Peixoto C, Ferreira TB, Sousa MFQ, Carrondo MJT, Alves PM. 2008. Towards purification of adenoviral vectors based on membrane technology. Biotechnol Prog 24:1290-1296.
108. Peixoto C, Sousa MFQ, Silva AC, Carrondo MJT, Alves PM. 2007. Downstream processing of triple layered rotavirus like particles. J Biotechnol 127:452-461.
109. Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser J, Tumpey TM. 2011. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29:5911-5918.
110. Rajendran A, Paredes G, Mazzotti M. 2009. Simulated moving bed chromatography for the separation of enantiomers. J Chromatogr A 1216:709-738.
111. Reimer C, Baker R, van Frank RM, Newlin T, Cline G, Anderson N. 1967. Purification of large quantities of influenza virus by density gradient centrifugation. J Virol 1:1207-1216.
112. van Reis R, Zydney A. 2006. Membrane processes in biotechnology: An overview. Biotechnol Adv 24:482-492.
113. van Reis R, Zydney A. 2007. Bioprocess membrane technology. J Memb Sci 297:16-50.
114. Riordan W, Heilmann S, Brorson K, Seshadri K, He Y, Etzel M. 2009. Design of salt-tolerant membrane adsorbers for viral clearance. Biotechnol Bioeng 103:920-929.
115. Rodrigues AF, Carrondo MJ, Alves PM, Coroadinha AS. 2014. Cellular targets for improved manufacturing of virus-based biopharmaceuticals in animal cells. Trends Biotechnol. 32:602-607.
116. Rodrigues T, Carrondo MJT, Alves PM, Cruz PE. 2007a. Purification of retroviral vectors for clinical application: Biological implications and technological challenges. J Biotechnol 127:520-541.
117. Rodrigues T, Carvalho A, Carmo M, Carrondo MJT, Alves PM, Cruz PE. 2007b. Scaleable purification process for gene therapy retroviral vectors. J Gene Med 9:233-243.
118. Roush DJ, Lu Y. 2008. Advances in primary recovery: Centrifugation and membrane technology. Biotechnol Prog 24:488-495.
119. Saito M, Kurosawa Y, Okuyama T. 2013. Scanning electron microscopy-based approach to understand the mechanism underlying the adhesion of dengue viruses on ceramic hydroxyapatite columns. PloS one 8:e53893.
120. Salmon F, Grosios K, Petry H. 2014. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera). Expert Rev Clin Pharmacol 7:53-65.
121. Segura MM, Kamen AA, Garnier A. 2011. Overview of current scalable methods for purification of viral vectors (pp. 89-116). Totowa, NJ: Humana Press.
122. Segura MM, Mangion M, Gaillet B, Garnier A. 2013. New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther 13:987-1011.
123. Segura MM, Puig M, Monfar M, Chillón M. 2012. Chromatography purification of canine adenoviral vectors. Hum Gene Ther Methods 23:182-197.
124. Seidel-Morgenstern A, Keffler LC, Kaspereit M. 2008. New developments in simulated moving bed chromatography. Chem Eng Technol 31:826-837.
125. Shanklin T, Roper K, Yegneswaran P, Marten MR. 2001. Selection of bioprocess simulation software for industrial applications. Biotechnol Bioeng 72:483-489.
126. Silva AC, Peixoto C, Lucas T, Küppers C, Cruz PE, Alves PM, Kochanek S. 2010a. Adenovirus vector production and purification. Curr Gene Ther 10:437-455.
127. Silva RJ, Rodrigues RC, Osuna-Sanchez H, Bailly M, Valéry E, Mota J. 2010b. A new multicolumn, open-loop process for center-cut separation by solvent-gradient chromatography. J Chromatogr A 1217:8257-8269.
128. Silva RJS, Rodrigues RCR, Mota JPB. 2012. Relay simulated moving bed chromatography: Concept and design criteria. J Chromatogr A 1260:132-142.
129. Singh N, Pizzelli K, Romero JK, Chrostowski J, Evangelist G, Hamzik J, Soice N, Cheng KS. 2013. Clarification of recombinant proteins from high cell density mammalian cell culture systems using new improved depth filters. Biotechnol Bioeng 110:1964-1972.
130. Smith J, Lipsitch M, Almond JW. 2011. Vaccine production, distribution, access, and uptake. Lancet 378:428-438.
131. Stonier A, Simaria AS, Smith M, Farid SS. 2012. Decisional tool to assess current and future process robustness in an antibody purification facility. Biotechnol Prog 28:1019-1028.
132. Subramanian S, Altaras GM, Chen J, Hughes BS, Zhou W, Altaras NE. 2008. Pilot-scale adenovirus seed production through concurrent virus release and concentration by hollow fiber filtration. Biotechnol Prog 21:851-859.
133. Tatsis N, Ertl HCJ. 2004. Adenoviruses as vaccine vectors. Mol Ther 10:616-629.
134. Thim L, Vandahl B, Karlsson J, Klausen N, Pedersen J, Krogh T, Kjalke M, Petersen J, Johnsen L, Bolt G, Nørby PL, Steenstrup TD. 2010. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 16:349-359.
135. Thomassen YE, van 't Oever AG, Vinke M, Spiekstra A, Wijffels RH, van der Pol LA, Bakker WAM. 2013. Scale-down of the inactivated polio vaccine production process. Biotechnol Bioeng 110:1354-1365.
136. Thomassen YE, van 't Oever AG, van Oijen MG, Wijffels RH, van der Pol LA, Bakker WA. 2013. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PloS one 8:e83374.
137. Tkacik G, Michaels S. 1991. A rejection profile test for ultrafiltration membranes & devices. Nat Biotechnol 9:941-946.
138. Vellinga J, Smith JP, Lipiec A, Majhen D, Lemckert A, van Ooij M, Ives P, Yallop C, Custers J, Havenga M. 2014. Challenges in manufacturing Adenoviral vectors for global vaccine product deployment. Hum Gene Ther 25:318-327.
139. Venkatachalam ARK, Szyporta M, Kiener TK, Balraj P, Kwang J. 2014. Concentration and purification of enterovirus 71 using a weak anion-exchange monolithic column. Virol J 11:99.
140. Vicente T, Faber R, Alves PM, Carrondo MJT, Mota JPB. 2011a. Impact of ligand density on the optimization of ion-exchange membrane chromatography for viral vector purification. Biotechnol Bioeng 108:1347-1359.
141. Vicente T, Mota JPB, Peixoto C, Alves PM, Carrondo MJT. 2011b. Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications: Current advances. Biotechnol Adv 29:869-878.
142. Vicente T, Peixoto C, Carrondo MJT, Alves PM. 2009. Purification of recombinant baculoviruses for gene therapy using membrane processes. Gene Ther 16:766-775.
143. Vicente T, Sousa MF, Peixoto C, Mota JP, Alves PM, Carrondo MJ. 2008. Anion exchange membrane chromatography for purification of rotavirus-like particles. J Membr Sci 311:270-283.
144. Villain L. 2014. Virus capture using membrane chromatography: improving selectivity by matrix design. Oral presentation, Recovery of Biological Products XVI Conference, Rostock, Germany.
145. Warikoo V, Godawat R, Brower K, Jain S, Cummings D, Simons E, Johnson T, Walther J, Yu M, Wright B, McLarty J, Karey KP, Hwang C, Zhou W, Riske F, Konstantinov K. 2012. Integrated continuous production of recombinant therapeutic proteins. Biotechnol Bioeng 109:3018-3029.
146. Weaver J, Husson SM, Murphy L, Wickramasinghe SR. 2013. Anion exchange membrane adsorbers for flow-through polishing steps: Part II. Virus, host cell protein, DNA clearance, and antibody recovery. Biotechnol Bioeng 110:500-510.
147. Wen EP, Ellis R, Pujar NS. 2014. Vaccine Development and Manufacturing. John Wiley & Sons.
148. Westoby M, Rogers JK, Haverstock R, Romero J, Pieracci J. 2011. Modeling industrial centrifugation of mammalian cell culture using a capillary based scale-down system. Biotechnol Bioeng 108:989-998.
149. Wickramasinghe SR, Kalbfuss B, Zimmermann A, Thom V, Reichl U. 2005. Tangential flow microfiltration and ultrafiltration for human in influenza A virus concentration and purification. Biotechnol Bioeng 92:199-208.
150. Wickramasinghe SR, Stump ED, Grzenia DL, Husson SM, Pellegrino J. 2010. Understanding virus filtration membrane performance. J Membr Sci 365:160-169.
151. Wolff MW, Reichl U. 2008. Downstream Processing: From Egg to Cell Culture-Derived Influenza Virus Particles. Chem Eng Technol 31:846-857.
152. Wolff MW, Reichl U. 2011. Downstream processing of cell culture-derived virus particles. Expert Rev Vaccines 10:1451-1475.
153. Wolff MW, Siewert C, Hansen SP, Faber R, Reichl U. 2010. Purification of cell culture derived modified vaccinia ankara virus by pseudo-affinity membrane adsorbers and hydrophobic interaction chromatography. Biotechnol Bioeng 107:312-320.
154. Woo M, Khan NZ, Royce J, Mehta U, Gagnon B, Ramaswamy S, Soice N, Morelli M, Cheng KS. 2011. A novel primary amine-based anion exchange membrane adsorber. J Chromatogr A 1218:5386-5392.
155. Yae K, Maiko S, Shintaro K, Tsuneo O. 2012. Purification of dengue virus particles by one-step ceramic hydroxyapatite chromatography. WJV 2012:155-160.
156. Yamamoto S, Nakamura M, Tarmann C, Jungbauer A. 2007. Retention studies of DNA on anion-exchange monolith chromatography Binding site and elution behavior. J Chromatogr A 1144:155-160.
157. Yigzaw Y, Piper R, Tran M, Shukla AA. 2006. Exploitation of the adsorptive properties of depth filters for host cell protein removal during monoclonal antibody purification. Biotechnol Prog 22:288-296.
158. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, Krishnamurty AT, Chang JT, Adams DJ, Hensley TR, Salter AI, Morgan CA, Duerr AC, De Rosa SC, Aderem A, McElrath MJ. 2012. Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. PNAS 109:E3503-E3512.
159. Zydney AL. 2009. Membrane technology for purification of therapeutic proteins. Biotechnol Bioeng 103:227-230.